SCD Pharma Consulting

Navigating Pharmaceutical Development
S. Craig Dyar, Ph.D., R.Ph.
During Craig’s 30 years in Pharmaceuticals, he developed extensive expertise in novel drug delivery systems and assessing external drug delivery companies while at Parke-Davis/Warner-Lambert, Pfizer and SCD Pharma Consulting. Craig has also been extensively involved in helping companies resolve drug development issues. He also managed a team of scientist developing novel drug delivery technologies and analytical techniques. Craig was also heavily involved in compound licensing and the associated technical due diligence activities. Throughout his years in the industry he has been heavily involved in intellectual property management and provided expert opinions on numerous patent matters, which included deposition and testimony in court.  He led a number of teams at Pfizer, including the COX-2 Franchise Team, Intellectual Property Team, Global Drug Delivery Team, and the Technology Board, which he also chaired. He was the Team Leader for Ophthalmology and a member of the Ophthalmology Development Teams where he served as the single point of accountability for all CMC aspects of the program.  In this role, he led several Project Teams in planning, tactics, problem solving, risk assessment, and scenario analysis. Later, he held the same position for the Dermatology portfolio.  He is a Senior Associate at Lachman Consultants. He is also President of SCD Pharma Consulting. A company providing consulting services in drug delivery R&D, project management, business development, expert patent witness, life-cycle management, technology assessment and drug development from discovery to post-launch.
Website Builder